Kenneth W. Duncan

1.2k citations

16 papers · 350 indexed · h-index 8

Co-authors: Christina R. Majer Richard Chesworth Nigel J. Waters Mikel P. Moyer Robert A. Copeland Michael J. Munchhof Christine Thompson Neil Johnson
Topics: Cancer-related gene regulation (8 papers)Epigenetics and DNA Methylation (6 papers)RNA modifications and cancer (3 papers)
Cited by: Molecular Biology Hematology Pharmacology
Journals: Blood PLoS ONE Cancer Research
Partner nations: United States United Kingdom Canada

In The Last Decade

Kenneth W. Duncan

14 papers receiving 336 citations

Peers

Countries citing papers authored by Kenneth W. Duncan

Since Specialization

Citations

This map shows the geographic impact of Kenneth W. Duncan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kenneth W. Duncan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kenneth W. Duncan more than expected).

Fields of papers citing papers by Kenneth W. Duncan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kenneth W. Duncan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kenneth W. Duncan. The network helps show where Kenneth W. Duncan may publish in the future.

Co-authorship network of co-authors of Kenneth W. Duncan

This figure shows the co-authorship network connecting the top 25 collaborators of Kenneth W. Duncan. A scholar is included among the top collaborators of Kenneth W. Duncan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kenneth W. Duncan. Kenneth W. Duncan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

#	Work	Indexed citations
1	Discovery of Kinesin KIF18A Inhibitor ATX020: Tactical Application of Silicon Atom Replacement 2025 ·ACS Medicinal Chemistry Letters ·Brian A. Sparling,Hyelee Lee,(unknown),(unknown),Simina Grigoriu,(unknown),G.J. Lockbaum,(unknown),(unknown),Young‐Tae Lee,Shane M. Buker,Deepali Gotur,Chuang Lu,Scott Ribich,Stephen J. Blakemore,P. Ann Boriack‐Sjodin,Serena J. Silver,Robert A. Copeland,Kenneth W. Duncan	0
2	Abstract PR003: DHX9 inhibition as a novel therapeutic for ovarian and breast cancer with loss-of-function mutations in the DNA damage repair genes BRCA1 or BRCA2 2024 ·Cancer Research ·(unknown),Matthew H. Daniels,(unknown),(unknown),(unknown),David Brennan,Brian Johnston,Anugraha Raman,Chuang Lu,Stephen J. Blakemore,Serena J. Silver,P. Ann Boriack‐Sjodin,Kenneth W. Duncan,Jason A. Sager,Robert A. Copeland	0
3	Abstract 3337: Inhibition of KIF18A leads to mitotic arrest and robust anti-tumor activity in chromosomally instable tumors 2024 ·Cancer Research ·Maureen S. Lynes,(unknown),(unknown),Brian A. Sparling,(unknown),Deepali Gotur,P. Ann Boriack‐Sjodin,Kenneth W. Duncan,Stephen J. Blakemore,Serena J. Silver,Robert A. Copeland	1
4	Abstract B073: Characterization of selective, allosteric inhibitors of human XRN1 2023 ·Molecular Cancer Therapeutics ·G.J. Lockbaum,E. Allen Sickmier,Brian A. Sparling,Kevin E. Knockenhauer,(unknown),Julie Liu,(unknown),Simina Grigoriu,Kenneth W. Duncan,Robert A. Copeland,P. Ann Boriack‐Sjodin	3
5	Abstract 1136: Targeting DHX9 inhibition as a novel therapeutic modality in microsatellite instable colorectal cancer 2023 ·Cancer Research ·(unknown),Matthew H. Daniels,Chuang Lu,David Brennan,Deepali Gotur,Young‐Tae Lee,Kevin E. Knockenhauer,April Case,(unknown),Shane M. Buker,Julie Liu,Brian A. Sparling,E. Allen Sickmier,Stephen J. Blakemore,P. Ann Boriack‐Sjodin,Kenneth W. Duncan,Scott Ribich,Robert A. Copeland	2
6	Abstract A170: Discovery of small molecule inhibitors of ADAR1 2023 ·Molecular Cancer Therapeutics ·Shane M. Buker,Stephen J. Blakemore,P. Ann Boriack‐Sjodin,Cindy Collins,Robert A. Copeland,Kenneth W. Duncan,Anna Ericsson,(unknown),April Greene-Colozzi,(unknown),G.J. Lockbaum,Anugraha Raman,Scott Ribich,E. Allen Sickmier,(unknown),(unknown),Serena J. Silver	2
7	Conformational-Design-Driven Discovery of EZM0414: A Selective, Potent SETD2 Inhibitor for Clinical Studies 2022 ·ACS Medicinal Chemistry Letters ·Joshua S. Alford,John W. Lampe,(unknown),Richard Chesworth,(unknown),Kenneth W. Duncan,Sean Eckley,Jeffrey L. Kutok,Alejandra Raimondi,Thomas V. Riera,Brian C. Shook,Cuyue Tang,(unknown),Neil A. Farrow	16
8	Pharmacologic Inhibition of the Histone Methyltransferase SETD2 with EZM0414 As a Novel Therapeutic Strategy in Relapsed or Refractory Multiple Myeloma and Diffuse Large B-Cell Lymphoma 2021 ·Blood ·(unknown),(unknown),(unknown),(unknown),(unknown),John W. Lampe,Thomas V. Riera,Cuyue Tang,Sean Eckley,(unknown),Kenneth W. Duncan,Neil A. Farrow,Daniel T. Dransfield,Alejandra Raimondi,(unknown),(unknown),Jeffery L. Kutok	2
9	Discovery of a First-in-Class Inhibitor of the Histone Methyltransferase SETD2 Suitable for Preclinical Studies 2021 ·ACS Medicinal Chemistry Letters ·John W. Lampe,Joshua S. Alford,(unknown),(unknown),(unknown),Kenneth W. Duncan,Sean Eckley,Megan A. Foley,(unknown),(unknown),Michael J. Munchhof,Alejandra Raimondi,Thomas V. Riera,Cuyue Tang,Michael J. Thomenius,(unknown),Neil A. Farrow	22
10	Activation of the p53-MDM4 regulatory axis defines the anti-tumour response to PRMT5 inhibition through its role in regulating cellular splicing 2018 ·Scientific Reports ·(unknown),Wendy A. Kellner,Christine Thompson,Melissa B. Pappalardi,Xiping Zhang,Rocío Montes de,(unknown),Kenneth W. Duncan,Ann Boriack-Sjodin,BaoChau Le,Christina R. Majer,Michael T. McCabe,Chris Carpenter,Neil Johnson,Ryan G. Kruger,Olena Barbash	121
11	Identification of a peptide inhibitor for the histone methyltransferase WHSC1 2018 ·PLoS ONE ·Michael J. Morrison,P. Ann Boriack‐Sjodin,Kerren K. Swinger,Tim J. Wigle,(unknown),Kevin W. Kuntz,Margaret Porter Scott,William P. Janzen,Richard Chesworth,Kenneth W. Duncan,(unknown),John W. Lampe,Lorna H. Mitchell,Robert A. Copeland	22
12	Identification of a First-in-Class SETD2 Inhibitor That Shows Potent and Selective Anti-Proliferative Activity in t(4;14) Multiple Myeloma: T(4;14) Multiple Myeloma Cells Are Dependent on Both H3K36 Di and Tri-Methylation 2018 ·Blood ·Michael J. Thomenius,(unknown),(unknown),(unknown),(unknown),Neil A. Farrow,J. Joshua Smith,Richard Chesworth,Kenneth W. Duncan,Cuyue Tang,Thomas V. Riera,John W. Lampe	3
13	Metabolism and disposition of the DOT1L inhibitor, pinometostat (EPZ-5676), in rat, dog and human 2015 ·Cancer Chemotherapy and Pharmacology ·Nigel J. Waters,Sherri Smith,Edward J. Olhava,Kenneth W. Duncan,Richard D. E. Burton,(unknown),(unknown),Roy M. Pollock,Mikel P. Moyer,Richard Chesworth	23
14	Species differences in metabolism of EPZ015666, an oxetane-containing protein arginine methyltransferase-5 (PRMT5) inhibitor 2015 ·Xenobiotica ·Nathalie Rioux,Kenneth W. Duncan,(unknown),Xiu‐Sheng Miao,Elayne Chan-Penebre,Mikel P. Moyer,Michael J. Munchhof,Robert A. Copeland,Richard Chesworth,Nigel J. Waters	16
15	Structure and Property Guided Design in the Identification of PRMT5 Tool Compound EPZ015666 2015 ·ACS Medicinal Chemistry Letters ·Kenneth W. Duncan,Nathalie Rioux,P. Ann Boriack‐Sjodin,Michael J. Munchhof,Lawrence A. Reiter,Christina R. Majer,Lei Jin,L. Danielle Johnston,Elayne Chan-Penebre,(unknown),Margaret Porter Scott,Roy M. Pollock,Nigel J. Waters,J. Joshua Smith,Mikel P. Moyer,Robert A. Copeland,Richard Chesworth	103
16	Small molecule tyrosine kinase inhibitors for the treatment of intestinal inflammation 2011 ·Inflammatory Bowel Diseases ·Maninder K. Sidhu,Carmen Alonso,Bayasi Guleng,Seiji Arihiro,Sun‐Young Chang,Kenneth W. Duncan,Alfred M. Ajami,MyDoanh Chau,Hans-Christian Reinecker	14

About Kenneth W. Duncan

Kenneth W. Duncan is a scholar working on Molecular Biology, Hematology and Immunology, having authored 16 papers that have together received 350 indexed citations. Recurring topics across this work include Cancer-related gene regulation (8 papers), Epigenetics and DNA Methylation (6 papers) and RNA modifications and cancer (3 papers). The work is most often cited by research in Molecular Biology (314 citations), Hematology (14 citations) and Pharmacology (9 citations). Kenneth W. Duncan has collaborated with scholars based in United States, United Kingdom and Canada. Frequent co-authors include Christina R. Majer, Richard Chesworth, Nigel J. Waters, Mikel P. Moyer, Robert A. Copeland, Michael J. Munchhof, Christine Thompson, Neil Johnson, Melissa B. Pappalardi and Ryan G. Kruger. Their work appears in journals such as Blood, PLoS ONE and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact